Table 1.

List of antibodies currently in clinical development. Data were extracted from National Institutes of Health databank (https://clinicaltrials.gov/; accessed on 20 April 2022), and the Antibody Society (https://www.antibodysociety.org/covid-19-biologics-tracker/; accessed on 10 May 2022).

	Antibody	Company and Country	Clinical Trial Stage and ID
1	REGN-COV2, a cocktail of two mAbs: REGN10987 (Imdevimab) and REGN10933 (Casirivimab)	Regeneron Pharmaceuticals, Westchester County, USA	Emergency Use Authorization granted in the USA; Approved in Japan, UK, EU, and Australia
2	LY-CoV555 (Bamlanivimab) and LY-CoV016 (Etesevimab)	AbCellera, Vancouver, Canada and Eli Lilly, Indianapolis, USA	Emergency Use Authorization granted in the USA in 2020, but limited the authorisation in 2022.
3	VIR-7831/ GSK4182136 (Sotrovimab)	Vir Biotechnology, San Francisco, USA and GSK, Middlesex, UK	Emergency Use Authorization granted in the USA; Approved in Australia, UK, and EU.
4	CT-P59 (Regdanvimab)	Celltrion Group, Incheon, South Korea	Emergency Use Authorization granted in South Korea and EU.
5	AZD7442 (AZD8895/Tixagevimab and AZD1061/Cilgavimab)	AstraZeneca, Macclesfield, UK	Emergency Use Authorization granted in the USA
6	TY027	Tychan, National University of Singapore	Phase 3 (NCT04429529 and NCT04649515)
7	BRII-196/ BRII-198 (Amu-barvimab/Romlusevimab)	Brii Bio, Durham, USA/TSB Therapeutics/Tsinghua University, China	Approved in China Phase 3 (NCT04501978, NCT04479631, and NCT04479644)
8	ADG20	Adagio Therapeutics, Waltham, USA	Phase 2/3 (NCT04805671 and NCT04859517)
9	SCTA01	Sinocelltech, China	Phase 2/3 (NCT04483375 and NCT04644185)
10	C144-LS and C-135-LS	Bristol-Myers Squibb, New York City, USA	Phase 2/3 (NCT04700163 and Activ-2 study)
11	ADM03820	Ology Bioservices, Alachua, USA	Phase 2/3 (NCT05142527)
12	REGN14256 + imdevimab	Regeneron, Westchester County, USA	Phase ½/3 (NCT05081388)
13	MAD0004J08	Toscana Life Sciences Sviluppo s.r.l, Siena, Italy	Phase 2/3 (NCT04932850 and NCT04952805)
14	MW33	Mabwell Bioscience Co, Zhangjiang Hi-tech Park, Shanghai	Phase 2 (NCT04533048 and NCT04627584)
15	Etesevimab (JS016, LY3832479, LY-CoV016)	Junshi Biosciences, China and Eli Lilly, Indianapolis, USA	Phase 2 (NCT04441918, NCT04441931, and NCT04427501)
16	BGB-DXP593	BeiGene, Beijing, China	Phase 2 (NCT04551898 and NCT04532294)
17	COVI-AMG (STI-2020)	Sorrento Therapeutics, San Diego, USA	Phase 2 (NCT04734860)
18	LY-CoV1404, LY3853113	AbCellera, Vancouver, Canada and Eli Lilly, Indianapolis, USA	Phase 2 (NCT04634409)
19	IBIO-123	Immune Biosolutions, Sherbrooke, Canada	Phase 2 (Not Available)
20	VIR-7832	Vir Biotechnology, San Francisco, USA	Phase 1/2 (NCT04746183)
21	COR-101	CORAT Therapeutics, Braunschweig, Germany	Phase 1/2 trial (NCT04674566)
22	DZIF-10c, BI 767551	University of Cologne, Germany	Phase 1/2 (NCT04631666 and NCT04631705)
23	XVR011	Exevir Bio BV, Belgium	Phase 1/2 (NCT04884295)
24	HLX70	Hengenix Biotech Inc., Milpitas, USA	Phase 1 (NCT04561076)
25	DXP-604	BeiGene, Beijing, China	Phase 1 (NCT04669262)
26	ZRC-3308	Zydus Cadila, Ahmedabad, India	Phase 1 (Not Available)
27	HFB30132A	HiFiBiO Therapeutics, Cambridge, USA	Phase 1 (NCT04590430)
28	ABBV-47D11	Abbvie, North Chicago, USA	Phase 1 (NCT04644120)
29	C144-LS and C-135-LS	Bristol-Myers Squibb, New York City, USA	Phase 1 (NCT04700163)
30	JMB2002	Jemincare Group, Shanghai	Phase 1 (ChiCTR2100042150)
31	IMM-BCP-01	Immunome, Inc., Exton, USA	Phase 1 (Not Available)
32	SCTA01	Sinocelltech, China	Phase 1 (NCT04483375)
33	MW33	Mabwell Bioscience Co., Ltd., Shanghai	Phase 1 (NCT04533048)
34	Anti-SARS-CoV-2 mAb	Stanford University, Stanford, USA	Phase 1 (NCT04567810)
35	P2C-1F11	Brii Biosciences, Durham, USA	Phase 1 (NCT04479631 and NCT04479644)
36	SCTA01	Sinocelltech, China	Phase 1 (NCT04483375)
37	LY-CovMab	Luye Pharma Group, Princeton, USA	Phase 1 (NCT04973735)
38	CT-P63	Celltrion Group, Incheon, South Korea	Phase 1 (NCT05017168)
39	IGM-6268	IGM Biosciences, Mountain View, USA	Phase 1 (NCT05160402 and NCT05184218)